International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors

被引:675
作者
Poyner, DR [1 ]
Sexton, PM
Marshall, I
Smith, DM
Quirion, R
Born, W
Muff, R
Fischer, JA
Foord, SM
机构
[1] Aston Univ, Inst Pharmaceut Sci, Birmingham B4 7ET, W Midlands, England
[2] Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia
[3] UCL, Dept Pharmacol, London, England
[4] AstraZeneca, Alderley Edge, Cheshire, England
[5] McGill Univ, Douglas Hosp Res Ctr, Verdun, PQ, Canada
[6] McGill Univ, Dept Psychiat, Verdun, PQ, Canada
[7] Univ Zurich, Klin Balgrist, Dept Orthoped Surg, Res Lab Calcium Metab, Zurich, Switzerland
[8] Univ Zurich, Klin Balgrist, Dept Med, Res Lab Calcium Metab, Zurich, Switzerland
[9] GlaxoSmithKline, Med Res Ctr, Stevenage, Herts, England
关键词
D O I
10.1124/pr.54.2.233
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The calcitonin family of peptides comprises calcitonin, amylin, two calcitonin gene-related peptides (CGRPs), and adrenomedullin. The first calcitonin receptor was cloned in 1991. Its pharmacology is complicated by the existence of several splice variants. The receptors for the other members the family are made up of subunits. The calcitonin-like receptor (CL receptor) requires a single transmembrane domain protein, termed receptor activity modifying protein, RAMP1, to function as a CGRP receptor. RAMP2 and -3 enable the same CL receptor to behave as an adrenomedullin receptor. Although the calcitonin receptor does not require RAMP to bind and respond to calcitonin, it can associate with the RAMPs, resulting in a series of receptors that typically have high affinity for amylin and varied affinity for CGRP. This review aims to reconcile what is observed when the receptors are reconstituted in vitro with the properties they show in native cells and tissues. Experimental conditions must be rigorously controlled because different degrees of protein expression may markedly modify pharmacology in such a complex situation. Recommendations, which follow International Union of Pharmacology guidelines, are made for the nomenclature of these multimeric receptors.
引用
收藏
页码:233 / 246
页数:14
相关论文
共 120 条
[51]  
Höppener JWM, 2000, NEW ENGL J MED, V343, P411
[52]   ISOFORMS OF THE RAT CALCITONIN RECEPTOR - CONSEQUENCES FOR LIGAND-BINDING AND SIGNAL-TRANSDUCTION [J].
HOUSSAMI, S ;
FINDLAY, DM ;
BRADY, CL ;
MYERS, DE ;
MARTIN, TJ ;
SEXTON, PM .
ENDOCRINOLOGY, 1994, 135 (01) :183-190
[53]  
HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798
[54]   Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function [J].
Husmann, K ;
Sexton, PM ;
Fischer, JA ;
Born, W .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2000, 162 (1-2) :35-43
[55]   The molecular pharmacology of CGRP and related peptide receptor subtypes [J].
Juaneda, C ;
Dumont, Y ;
Quirion, R .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2000, 21 (11) :432-438
[56]   Identification of an orphan receptor gene as a type 1 calcitonin gene-related peptide receptor [J].
Kapas, S ;
Clark, AJL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 217 (03) :832-838
[57]   CLONING AND EXPRESSION OF CDNA-ENCODING A RAT ADRENOMEDULLIN RECEPTOR [J].
KAPAS, S ;
CATT, KJ ;
CLARK, AJL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (43) :25344-25347
[58]   Expression of the rat adrenomedullin receptor or a putative human adrenomedullin receptor does not correlate with adrenomedullin binding or functional response [J].
Kennedy, SP ;
Sun, DX ;
Oleynek, JJ ;
Hoth, CF ;
Kong, J ;
Hill, RJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 244 (03) :832-837
[59]   ADRENOMEDULLIN - A NOVEL HYPOTENSIVE PEPTIDE ISOLATED FROM HUMAN PHEOCHROMOCYTOMA [J].
KITAMURA, K ;
KANGAWA, K ;
KAWAMOTO, M ;
ICHIKI, Y ;
NAKAMURA, S ;
MATSUO, H ;
ETO, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 192 (02) :553-560
[60]  
KUESTNER RE, 1994, MOL PHARMACOL, V46, P246